HeartFlow vs Lunit
HeartFlow analyses coronary CT angiograms. Lunit works on chest films, mammograms and tomosynthesis. A hospital cardiac CT program that wants fractional flow reserve and plaque measurements from the vendor's cloud takes HeartFlow, whose first FFRct clearance was a De Novo in 2014 and whose Plaque Analysis later cleared through 510(k). A breast imaging center or a chest-film service takes Lunit, which holds 510(k) clearances for INSIGHT CXR Triage, INSIGHT MMG and INSIGHT DBT. The listed chest X-ray clearance is for triage only. A prospective multicenter Lunit study of 4,752 cases (Diagnostics, 2023) reported AUC 0.84, against 0.94 retrospectively. On cost, HeartFlow's 10-K describes revenue as pay-per-use, so a cardiac lab pays by case, while a breast center gets a Lunit quote through a contact form.
Radiology · Reviewed November 2, 2026

HeartFlow
by HeartFlow · founded 2007
Coronary CT angiogram analysis: CT-derived fractional flow reserve (FFRct), plaque analysis and a CCTA reading aid.

Lunit
by Lunit · founded 2013
AI for chest X-ray, mammography and breast tomosynthesis, Volpara breast-density tools, and pathology biomarker software (SCOPE).
When to pick each one
HeartFlow
- Fractional flow reserve from a coronary CTA
- Pay-per-use model, per the 10-K
Lunit
- 510(k) clearances for CXR triage, mammography, tomosynthesis
- SCOPE pathology suite for biomarker work
Score
Each row shows points earned of points available under the published rubric.
HeartFlow
66of 100
Lunit
66of 100
| Dimension | HeartFlow | Lunit | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 12.7 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 7.8 / 7.8 | 7.8 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 6 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
HeartFlow
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Per study | n/a | n/a | No public list price. The 10-K describes revenue as pay-per-use. |
Lunit
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Evidence
HeartFlow
FDA decisions
K250902 (opens in new tab)510(k)2025-07-18
HeartFlow Analysis
K213857 (opens in new tab)510(k)2022-10-14
HeartFlow Analysis
K203329 (opens in new tab)510(k)2021-01-08
HeartFlow Analysis
K190925 (opens in new tab)510(k)2019-08-15
K182035 (opens in new tab)510(k)2018-12-06
Show 3 more
K161772 (opens in new tab)510(k)2016-08-24
K152733 (opens in new tab)510(k)2016-01-13
DEN130045 (opens in new tab)De Novo2014-11-26
FFRct
Peer-reviewed
2 PubMed records name HeartFlow.
- Prognostic value of CT-derived fractional flow reserve for major adverse cardiovascular events in patients with suspected or known coronary artery disease: a systematic review and meta-analysis. (opens in new tab)
- Diagnostic Performance of AI-enabled Plaque Quantification from Coronary CT Angiography Compared with Intravascular Ultrasound. (opens in new tab)
Lunit
FDA decisions
K260320 (opens in new tab)510(k)2026-04-23
Lunit INSIGHT MMG (v1.1.10)
K253796 (opens in new tab)510(k)2026-03-26
Lunit INSIGHT DBT (V1.2)
K242652 (opens in new tab)510(k)2024-10-04
Lunit INSIGHT DBT v1.1
K231470 (opens in new tab)510(k)2023-11-06
Lunit INSIGHT DBT
K211678 (opens in new tab)510(k)2021-11-17
Lunit INSIGHT MMG
Show 3 more
K211733 (opens in new tab)510(k)2021-11-10
Lunit INSIGHT CXR Triage
K211279 (opens in new tab)510(k)2021-07-27
Volpara Imaging Software
K182310 (opens in new tab)510(k)2018-09-21
Volpara Imaging Software
Peer-reviewed
3 PubMed records name Lunit.
- Comparison of different Lunit INSIGHT CXR software versions when reading chest radiographs for tuberculosis. (opens in new tab)
- Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). (opens in new tab)
- Long-term prognostic implications of AI-detected versus AI-undetected breast cancers on mammography: a propensity score-matched analysis. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | HeartFlow | Lunit |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2007 | 2013 |
| HQ | US | KR |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.
